Comparison of the Efifcacy and Safety of Icotinib with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2015.06.07
- VernacularTitle:埃克替尼对比标准二线化疗治疗晚期非小细胞肺癌的临床观察
- Author:
YAO SHUYANG
1
;
QIAN KUN
;
WANG RUOTIAN
;
LI YUANBO
;
ZHANG YI
Author Information
1. 首都医科大学宣武医院胸外科
- Keywords:
Lung neoplasms;
Icotinib;
Chemotherapy
- From:
Chinese Journal of Lung Cancer
2015;(6):369-373
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective This study compared the efficacy and safety of icotinib with standard second-line chemotherapy (single-agent docetaxel or pemetrexed) in previously treated advanced non-small cell lung cancer (NSCLC).Methods hTirty-two consecutive patients treated with icotinib and 33 consecutive patients treated with standard second-line chemotherapy in Xuanwu Hospital from January 2012 to July 2013 were enrolled in our retrospective research. hTe Response Evaluation Criteria in Solid Tumors were used to evaluate the tumor responses, and the progression-free survival (PFS) was evaluated byKaplan-Meiermethod.Results Icotinib was comparable with standard second-line chemotherapy for advanced NSCLC in terms of overall response rate (ORR) (28.1%vs18.2%,P=0.341), disease control rate (DFS)(43.8%vs 45.5%,P=0.890), and PFS (4.3 monthsvs 3.8 months,P=0.506). In the icotinib group, the ORR of epidermal growth factor receptor (EGFR) mutant was signiifcantly higher than that of EGFR unknown or wild type (P=0.017). In multivariate analysis, age, gender, histology, and the optimum ifrst-line treatment response were dependent prognostic factors based on the PFS of the icotinib group. hTe incidence of adverse events was signiifcantly fewer in the icotinib group than in the chemotherapy group (P=0.001).Conclusion Compared with the standard second-line chemotherapy, icotinib is active in the treatment of advanced NSCLC patients, especially with EGFR unknown in the second line, with an acceptable adverse event proifle.
